Aeterna Zentaris Announces At the Market Issuance Program
April 01 2016 - 5:05PM
Business Wire
All dollar amounts are stated in US$
Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the “Company”)
announced today that it has entered into an At Market Issuance
("ATM") Sales Agreement, dated April 1, 2016, with H.C. Wainwright
& Co., LLC (the “Sales Agent”), under which the Company may, at
its discretion, from time to time during the term of the ATM Sales
Agreement, sell up to a maximum of 3,000,000 of its common shares
through ATM issuances on the NASDAQ Stock Market, up to an
aggregate amount of approximately $10 million. The Sales Agent will
act as sales agent for any sales made under this new ATM program.
The common shares will be sold at market prices prevailing at the
time of the sale of the common shares and, as a result, sale prices
may vary.
In connection with the execution of the ATM Sales Agreement with
the Sales Agent, the Company has filed with the United States
Securities and Exchange Commission (the “SEC”) a prospectus
supplement to its shelf registration statement on Form F-3
(333-194547) filed with the SEC on March 14, 2014, which was
declared effective by the SEC on March 28, 2014.
The shelf registration statement on Form F-3 and the prospectus
supplement for this offering are available on the SEC’s website
(www.sec.gov). Alternatively, the Sales Agent will provide copies
of these documents upon request by contacting H.C. Wainwright &
Co., LLC, 430 Park Avenue, 4th Floor, New York, NY 10022 at
placements@hcwco.com.
This press release does not and shall not constitute an offer to
sell or the solicitation of an offer to buy any of the common
shares, nor shall there be any sale of the common shares in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of such state or jurisdiction.
About Aeterna Zentaris
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women’s health. We are engaged in drug
development activities and in the promotion of products for others.
We are now conducting Phase 3 studies of two internally developed
compounds. The focus of our business development efforts is the
acquisition of licenses to products that are relevant to our
therapeutic areas of focus. We also intend to license out certain
commercial rights of internally developed products to licensees in
territories where such out-licensing would enable us to ensure
development, registration and launch of our product candidates. Our
goal is to become a growth-oriented specialty biopharmaceutical
company by pursuing successful development and commercialization of
our product portfolio, achieving successful commercial presence and
growth, while consistently delivering value to our shareholders,
employees and the medical providers and patients who will benefit
from our products. For more information, visit www.aezsinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160401005894/en/
Aeterna Zentaris Inc.Philip A. TheodoreSenior Vice
President843-900-3223ir@aezsinc.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024